UNSPSC 51392004: Sulfonterol

This classification denotes a beta-adrenergic agonist with the molecular formula C14H23NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z540ZT2MI6, chemically known as benzenemethanol, alpha-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-3-((methylsulfonyl)methyl)- but generally known as sulfonterol, which bears US NIH Compound Identifier 170373. European Medicines Agency schedules Sulfonterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10741MIG.

UNSPSC 51392004 Sulfonterol is a Commodity code. The recent state and local opportunities tagged under this code do not align with sulfonterol—a long-acting beta-2 agonist pharmaceutical product—but rather reflect procurement of naloxone (opioid-reversal medication) and pharmacy benefit management services. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, with quarterly deliveries to the county health building and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 as preliminary market intelligence gathering for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring vendor capabilities for direct contracting between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager arrangements. The mismatch between the code's nominal scope and the actual solicitations suggests this code shows limited relevant recent activity in state and local procurement.

Activity under this code appears concentrated in Florida and Texas based on the two recent opportunities. Seminole County represents a local health department approach to naloxone procurement driven by opioid-response initiatives, while the Texas RFI signals state-level interest in restructuring pharmacy benefit administration and manufacturer relationships. Neither opportunity is soliciting sulfonterol as a product line; the code may be incorrectly applied by issuing bodies or may see minimal attachment to actual state and local pharmaceutical product procurement.